Published in Sci Rep on March 30, 2017
Emergence of Zaire Ebola virus disease in Guinea. N Engl J Med (2014) 16.45
Reversion of advanced Ebola virus disease in nonhuman primates with ZMapp. Nature (2014) 6.94
Clinical care of two patients with Ebola virus disease in the United States. N Engl J Med (2014) 5.74
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis (1998) 4.50
Identification of the Ebola virus glycoprotein as the main viral determinant of vascular cell cytotoxicity and injury. Nat Med (2000) 4.36
Delayed treatment of Ebola virus infection with plant-derived monoclonal antibodies provides protection in rhesus macaques. Proc Natl Acad Sci U S A (2012) 2.83
Neutralizing antibody fails to impact the course of Ebola virus infection in monkeys. PLoS Pathog (2007) 2.64
Treatment of Ebola virus disease. Intensive Care Med (2014) 2.33
Generation of eGFP expressing recombinant Zaire ebolavirus for analysis of early pathogenesis events and high-throughput antiviral drug screening. Virology (2005) 2.25
A mouse model for evaluation of prophylaxis and therapy of Ebola hemorrhagic fever. J Infect Dis (1999) 2.24
Ebola virus-like particles protect from lethal Ebola virus infection. Proc Natl Acad Sci U S A (2003) 2.18
Mucosal immunization of cynomolgus macaques with the VSVDeltaG/ZEBOVGP vaccine stimulates strong ebola GP-specific immune responses. PLoS One (2009) 1.83
Immune parameters correlate with protection against ebola virus infection in rodents and nonhuman primates. Sci Transl Med (2012) 1.83
Pathogenesis of experimental Ebola Zaire virus infection in BALB/c mice. J Comp Pathol (2001) 1.75
Ebolavirus glycoprotein structure and mechanism of entry. Future Virol (2009) 1.56
Protective efficacy of neutralizing antibodies against Ebola virus infection. Vaccine (2006) 1.38
Protective monotherapy against lethal Ebola virus infection by a potently neutralizing antibody. Science (2016) 1.29
Molecular characterization of the monoclonal antibodies composing ZMAb: a protective cocktail against Ebola virus. Sci Rep (2014) 1.24
A systematic study of the N-glycosylation sites of HIV-1 envelope protein on infectivity and antibody-mediated neutralization. Retrovirology (2013) 1.17
The Ebola virus glycoprotein contributes to but is not sufficient for virulence in vivo. PLoS Pathog (2012) 1.16
Virus nomenclature below the species level: a standardized nomenclature for laboratory animal-adapted strains and variants of viruses assigned to the family Filoviridae. Arch Virol (2013) 1.16
Lethality and pathogenesis of airborne infection with filoviruses in A129 α/β -/- interferon receptor-deficient mice. J Med Microbiol (2011) 1.13
Optimization of primer sequences for mouse scFv repertoire display library construction. Nucleic Acids Res (1994) 1.11
Mouse models for filovirus infections. Viruses (2012) 1.07
Shed GP of Ebola virus triggers immune activation and increased vascular permeability. PLoS Pathog (2014) 1.06
Application of bioluminescence imaging to the prediction of lethality in vaccinia virus-infected mice. J Virol (2009) 1.00
Isolation of potent neutralizing antibodies from a survivor of the 2014 Ebola virus outbreak. Science (2016) 0.97
Two-mAb cocktail protects macaques against the Makona variant of Ebola virus. Sci Transl Med (2016) 0.91
Less is more: Ebola virus surface glycoprotein expression levels regulate virus production and infectivity. J Virol (2014) 0.88
Development of therapeutics for treatment of Ebola virus infection. Microbes Infect (2014) 0.86
A novel high-throughput vaccinia virus neutralization assay and preexisting immunity in populations from different geographic regions in China. PLoS One (2012) 0.86
Comparison of the replication characteristics of vaccinia virus strains Guang 9 and Tian Tan in vivo and in vitro. Arch Virol (2014) 0.80
A safe and sensitive enterovirus A71 infection model based on human SCARB2 knock-in mice. Vaccine (2016) 0.79
An Ebola Virus-Like Particle-Based Reporter System Enables Evaluation of Antiviral Drugs In Vivo under Non-Biosafety Level 4 Conditions. J Virol (2016) 0.79
Characterization of the inhibitory effect of an extract of Prunella vulgaris on Ebola virus glycoprotein (GP)-mediated virus entry and infection. Antiviral Res (2016) 0.77
Bioluminescent imaging of vaccinia virus infection in immunocompetent and immunodeficient rats as a model for human smallpox. Sci Rep (2015) 0.77
What is Ebola? Int J Clin Pract (2014) 0.77
Pseudoparticle neutralization assay for detecting ebola- neutralizing antibodies in biosafety level 2 settings. Clin Chem (2015) 0.77